| abstract |
Compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells are disclosed. An isolated nucleic acid sequence encoding CAR is also disclosed. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ. |